Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Top Cited Papers
Open Access
- 1 February 2021
- journal article
- research article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 23 (2), 120-127
- https://doi.org/10.1089/dia.2020.0388
Abstract
Background:The t:slim X2 (TM) insulin pump with Control-IQ (TM) technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. Methods:Individuals with type 1 diabetes (T1D) (>= 14 years of age) who had >= 21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). Patient-reported outcomes (PROs) and glycemic outcomes were reviewed at each timepoint. Results:Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect(R)web application. Time in range was 78.2% (70.2%-85.1%) at T1 and 79.2% (70.3%-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system. Conclusions:Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended TIR glycemic outcomes in people with T1D.Keywords
This publication has 26 references indexed in Scilit:
- Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software UpdateEndocrine Practice, 2020
- Glycemic Outcomes for People with Type 1 and Type 2 Diabetes Using Control-IQ Technology: Real-World Data from Early AdoptersDiabetes, 2020
- Control-IQ Technology in the Real World: The First 30 DaysDiabetes, 2020
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesThe New England Journal of Medicine, 2019
- Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent CohortDiabetes Technology & Therapeutics, 2019
- Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial LaunchDiabetes Technology & Therapeutics, 2018
- Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 DiabetesCurrent Diabetes Reports, 2018
- Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG StudyDiabetes, 2018
- Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial SubstudyJournal of Diabetes Science and Technology, 2017
- Impact of Chronic Sleep Disturbance for People Living With T1 DiabetesJournal of Diabetes Science and Technology, 2015